RELX Plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $12.9B+9.2% YoYTTM through 31 Dec 2025
Net Income $2.8B+14.7% YoYTTM through 31 Dec 2025
Free Cash Flow $3.8BTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| EBITDA Margin | 39.4% |
| Operating Margin | 31.6% |
| Net Margin | 21.5% |
Returns
86.3%ROE
14.0%ROA
Balance Sheet Health
Current Ratio0.49x
Cash & Equivalents$131M
Quality Metrics
Piotroski F-Score6 / 9
FCF Margin29.4%
Rule of 4034.6
Multi-Year Trend
RevenueFY2021: $7.2B
Diluted EPSFY2025: $1.12
Dividend
$0.66Per share, FY20261.99%Yield-0.4%5-yr growth
Capital Allocation
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Risk | $3.5B | +8.0% | View detailsExpect continued strong underlying growth in revenue and adjusted operating profit. |
| Scientific, Technical & Medical | $2.7B | +5.0% | View detailsExpect good growth with improving momentum. |
| Legal | $1.8B | +9.0% | View detailsExpect a further step up in growth. |
| Exhibitions | $1.2B | +8.0% | View detailsExpect strong ongoing growth. |
Financials converted at 0.7425 from GBP.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.